Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: A randomized phase II trial

Oncology

Volumn 74, Issue 3-4, 2008, Pages 223-228

  Boccardo, Francesco ^a   Rubagotti, Alessandra ^a   Conti, Giario ^b   Battaglia, Michele ^c   Cruciani, Giorgio ^d   Manganelli, Antonio ^e   Ricci, Sergio ^f   Lapini, Alberto ^g  

^a UNIVERSITY OF GENOA   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

^c POLICLINICO   (Italy)

^d Umberto I Hospital   (Italy)

^e UNIVERSITY HOSPITAL OF SIENA   (Italy)

^f UNIVERSITY OF PISA   (Italy)

^g CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Gefitinib; Hormone refractory prostate cancer; Prednisone

Indexed keywords

GEFITINIB; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; ERYTHEMA; FEVER; FOLLOW UP; HUMAN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAIL DISEASE; NAUSEA AND VOMITING; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DOUBLE-BLIND METHOD; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PLACEBOS; PREDNISONE; PROGNOSIS; PROSTATIC NEOPLASMS; QUINAZOLINES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 49549117313     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151391     Document Type: Article

References (25)

1. Smaletz O, Scher HI, Small EJ, et al: Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002;20:3972-3982.
2. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
3. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
4. Tillotson JK, Rose DP: Density-dependent regulation of epidermal growth factor receptor expression in DU 145 prostate cancer cells. Prostate 1991;19:53-61.
5. Di Lorenzo G, Tortora G, D'Armiento FP, et al: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-3444.
6. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
7. Sirotnak FM, She Y, Lee F, Chen J, Scher HI: Studies with CWR22 xenografts in nude mice suggest that ZD1839 (Iressa) may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 2002;8:3870-3876.
8. Bonaccorsi L, Marchiani S, Muratori M, Forti G, Baldi E: Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. J Cancer Res Clin Oncol 2004;130:604-614.
9. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
10. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
11. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. 2. Analysis and examples. Br J Cancer 1977;35:1-39.
12. Sargent DJ, Goldberg RM: A flexible design for multiple armed screening trials. Stat Med 2001;20:1051-1060.
13. Schroder FH, Wildhagen MF: ZD1839 (gefitinib) and hormone resistant (HR) prostate cancer - final results of a double blind randomized placebo-controlled phase II study (abstract 4698). ASCO Annu Meet Proc, 2004, vol 23, p 429.
14. Rosenthal M, Toner GC, Gurney H, et al: Inhibition of the epidermal growth factor receptor (EGFR) in hormone refractory prostate cancer (HRPC): initial results of a phase II trial of Gefitinib (abstract 1671). Proc Am Soc Clin Oncol 2003;21:416.
15. Canil CM, Moore MJ, Winquist E, et al: Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2005;23:455-460.
16. Small EJ, Fontana J, Tannir N, et al: A phase II trial of gefitinib in patients with non-metastatic hormone refractory prostate cancer. BJU Int 2007;100:765-769.
17. Baselga J, Rischin D, Ranson M, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-4302.
18. Festuccia C, Gravina GL, Muzi P, et al: Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients. Oncol Rep 2007;18:1321-1327.
19. Mimeault M, Venkatraman G, Johansson SL, et al: Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int J Cancer 2006;120:160-169.
20. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;351:2129-2139.
21. Curigliano G, Pelosi G, De Pas T, et al: Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. Prostate 2007;67:603-604.
22. Yano S, Matsuyama H, Hirata H, et al: Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep 2006;15:1453-1460.
23. Schmitz M, Grignard G, Margue C, et al: Complete loss of the PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007;120:1284-1292.
24. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-3467.
25. Swaisland HC, Cantarini MV, Fuhr R, Holt A: Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin Pharmacokinet 2006;45:633-644.